304 related articles for article (PubMed ID: 33626218)
1. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
[TBL] [Abstract][Full Text] [Related]
2. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
[TBL] [Abstract][Full Text] [Related]
3. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Imai H; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Nakajima T; Takahashi T
Med Oncol; 2014 Aug; 31(8):88. PubMed ID: 24961467
[TBL] [Abstract][Full Text] [Related]
4. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J
Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604
[TBL] [Abstract][Full Text] [Related]
5. Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Mori K; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Oncology; 2021; 99(9):562-570. PubMed ID: 34237736
[TBL] [Abstract][Full Text] [Related]
6. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
Yano Y; Kurebe H; Edahiro R; Hosono Y; Nakatsubo S; Nishida K; Sawa N; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
PLoS One; 2018; 13(8):e0203070. PubMed ID: 30153300
[TBL] [Abstract][Full Text] [Related]
7. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
[TBL] [Abstract][Full Text] [Related]
8. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
10. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab.
Araki T; Tateishi K; Sonehara K; Hirota S; Komatsu M; Yamamoto M; Kanda S; Kuraishi H; Hanaoka M; Koizumi T
Thorac Cancer; 2021 Mar; 12(5):603-612. PubMed ID: 33434414
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
13. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
17. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
[TBL] [Abstract][Full Text] [Related]
19. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
[TBL] [Abstract][Full Text] [Related]
20. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
